PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Aug 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for women with early-stage endometrial cancer, specifically those with a type called mismatch repair-deficient (MMRd) endometrial cancer. The goal is to see if combining a medication known as a PD-1 inhibitor with progesterone can help these women preserve their ability to have children while managing their cancer. This trial is particularly focused on younger women, aged 18 to 45, who have been diagnosed with early-stage cancer and have a strong desire to maintain their fertility.

To participate in the trial, women must meet certain criteria, including being between 18 and 45 years old, having a specific type of early-stage cancer (Stage IA), and having a confirmed diagnosis of a less aggressive form of cancer (G1-G2). Participants will need to provide informed consent, meaning they agree to take part in the study after understanding what it involves. While the trial is not yet recruiting participants, it aims to offer a hopeful option for women who want to balance cancer treatment with their dreams of having children.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Be between the ages of 18-45 years old;
• • Stage IA (FIGO 2009) ;
• • Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\&C or hysteroscopy;
• • Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR);
• • With a strong desire for fertility preservation;
• • Sign the informed consent.
• Exclusion Criteria:
• • Stage IB(FIGO 2009) and above；
• • Tumour differentiation of G3 or non-endometrioid adenocarcinoma；
• • Complicated with any other malignancy；
• • Contraindicated to conservative treatment or the use of pharmaceuticals.
• • Contraindications to pregnancy, or judged by the researcher to be unfit for pregnancy or delivery.